Literature DB >> 22639159

Mechanisms of immune evasion by gliomas.

Cleo E Rolle1, Sadhak Sengupta, Maciej S Lesniak.   

Abstract

A major contributing factor to glioma development and progression is its ability to evade the immune system. This chapter will explore the mechanisms utilized by glioma to mediate immunosuppression and immune evasion. These include intrinsic mechanisms linked to its location within the brain and interactions between glioma cells and immune cells. Lack of recruitment of naïve effector immune cells perhaps accounts for most of the immune suppression mediated by these tumor cells. This is enhanced by increased recruitment of microglia which resemble immature antigen presenting cells that are unable to support T-cell mediated immunity. Furthermore, secreted factors like TGF-β, COX-2 and IL-10, altered costimulatory molecules and inhibition of STAT-3 all contribute to the recruitment and expansion of regulatory T cells, which further modulate the immunosuppressive environment of glioma. In light of these findings, multiple immunotherapeutic treatment modalities are currently being explored.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22639159     DOI: 10.1007/978-1-4614-3146-6_5

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  51 in total

1.  Medium dose intermittent cyclophosphamide induces immunogenic cell death and cancer cell autonomous type I interferon production in glioma models.

Authors:  Bin Du; David J Waxman
Journal:  Cancer Lett       Date:  2019-11-22       Impact factor: 8.679

2.  Methotrexate up-regulates ecto-5'-nucleotidase/CD73 and reduces the frequency of T lymphocytes in the glioblastoma microenvironment.

Authors:  Fabrício Figueiró; Catiúscia P de Oliveira; Letícia S Bergamin; Liliana Rockenbach; Franciane B Mendes; Elisa Helena F Jandrey; Cesar Eduardo J Moritz; Letícia F Pettenuzzo; Jean Sévigny; Silvia S Guterres; Adriana R Pohlmann; Ana Maria O Battastini
Journal:  Purinergic Signal       Date:  2016-02-24       Impact factor: 3.765

3.  The novel immunotherapeutic molecule T11TS modulates glioma-induced changes of key components of the immunological synapse in favor of T cell activation and glioma abrogation.

Authors:  Suhnrita Chaudhuri; Manoj Kumar Singh; Debanjan Bhattacharya; Sagar Acharya; Sirshendu Chatterjee; Pankaj Kumar; Pushpak Bhattacharjee; Anjan Kumar Basu; Gaurisankar Sa; Tanya Das; Tushar Kanti Ghosh; Swapna Chaudhuri
Journal:  J Neurooncol       Date:  2014-07-16       Impact factor: 4.130

4.  The therapeutic efficacy of the oncolytic virus Delta24-RGD in a murine glioma model depends primarily on antitumor immunity.

Authors:  Anne Kleijn; Jenneke Kloezeman; Elike Treffers-Westerlaken; Giulia Fulci; Sieger Leenstra; Clemens Dirven; Reno Debets; Martine Lamfers
Journal:  Oncoimmunology       Date:  2014-12-13       Impact factor: 8.110

5.  Oxaliplatin disrupts pathological features of glioma cells and associated macrophages independent of apoptosis induction.

Authors:  Nathan B Roberts; Aymen Alqazzaz; Jacqueline R Hwang; Xiulan Qi; Achsah D Keegan; Anthony J Kim; Jeffrey A Winkles; Graeme F Woodworth
Journal:  J Neurooncol       Date:  2018-08-21       Impact factor: 4.130

6.  Immune heterogeneity and clinicopathologic characterization of IGFBP2 in 2447 glioma samples.

Authors:  Jinquan Cai; Qun Chen; Yuqiong Cui; Jiawei Dong; Meng Chen; Pengfei Wu; Chuanlu Jiang
Journal:  Oncoimmunology       Date:  2018-02-13       Impact factor: 8.110

Review 7.  Repurposing platinum-based chemotherapies for multi-modal treatment of glioblastoma.

Authors:  Nathan B Roberts; Aniket S Wadajkar; Jeffrey A Winkles; Eduardo Davila; Anthony J Kim; Graeme F Woodworth
Journal:  Oncoimmunology       Date:  2016-08-19       Impact factor: 8.110

Review 8.  Cyclooxygenase-2 in glioblastoma multiforme.

Authors:  Jiange Qiu; Zhi Shi; Jianxiong Jiang
Journal:  Drug Discov Today       Date:  2016-09-28       Impact factor: 7.851

9.  Inflammation and Gliomagenesis: Bi-Directional Communication at Early and Late Stages of Tumor Progression.

Authors:  Rui Pedro Galvão; Hui Zong
Journal:  Curr Pathobiol Rep       Date:  2013-03-01

Review 10.  Extracellular vesicles shed by glioma cells: pathogenic role and clinical value.

Authors:  Dimitry A Chistiakov; Vladimir P Chekhonin
Journal:  Tumour Biol       Date:  2014-06-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.